Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

NCT00897143 | Withdrawn DMC

• 2 other identifiers: CASE1507P30CA043703
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future. PURPOSE: This laboratory study is looking at malignant pleural effusion samples from patients with primary lung cancer to see if early lung cancer cells can be identified.

Conditions

Lung Cancer; Metastatic Cancer

Keywords

non-small cell lung cancer; malignant pleural effusion; small cell lung cancer

Outcome Measures

Primary Outcomes (1)

• Isolation and identification of lung cancer precursor cells in malignant pleural effusion specimens

Interventions

microarray analysis GENETIC

analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin

mutation analysis GENETIC

analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin

flow cytometry OTHER

analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin

immunologic technique OTHER

analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Malignant pleural effusion samples from patients with primary lung cancer.

DISEASE CHARACTERISTICS: * Cytologically positive malignant pleural effusion secondary to primary small cell or non-small cell lung cancer * Recruited from the Division of Hematology/Oncology, the Multidisciplinary Thoracic Oncology Group of Ireland Cancer Center, or the inpatient or outpatient units of Case Medical Center-University Hospitals PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Case Comprehensive Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Cleveland, Ohio, 44106-5065, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Malignant pleural effusion specimens from patients with primary lung cancer obtained from the Pathology Department at the University Hospitals of Cleveland.

MeSH Terms

Conditions

Lung Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Pleural Effusion, Malignant; Small Cell Lung Carcinoma

Interventions

Microarray Analysis; Flow Cytometry; Immunologic Techniques

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Pleural Neoplasms; Pleural Effusion; Pleural Diseases

Intervention Hierarchy (Ancestors)

Microchip Analytical Procedures; Investigative Techniques; Cell Separation; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Cytophotometry; Fluorometry; Luminescent Measurements; Photometry; Chemistry Techniques, Analytical

Study Officials

• Balazs Halmos, MD

  Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: June 1, 2007
• Last Updated: October 9, 2015

Record last verified: 2015-10

Locations

US (1)